| Bioactivity | LZ9 is a ATP-competitive CDK1 and CDK2 inhibitor. LZ9 has the potential for the research of colorectal cancer (CRC)[1][2]. |
| CAS | 844441-29-8 |
| Formula | C17H11F3N4O2 |
| Molar Mass | 360.29 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lu Z, et al. Computational design of CDK1 inhibitors with enhanced target affinity and drug-likeness using deep-learning framework. Heliyon. 2024 Nov 14;10(22):e40345. [2]. Ogbodo UC, et al. Computational identification of potential inhibitors targeting cdk1 in colorectal cancer. Front Chem. 2023 Nov 30;11:1264808. |